{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-087217","form_type":"8-K/A","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.967110+00:00","generated_at":"2026-05-17T06:44:00.551258+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vyome corrected pro forma statements show combined net loss $522k, revenue $249k for H1 2025","bullets":["Corrected pro forma for H1 2025: combined net loss $522k, revenue $249k, EPS $(0.07).","Vyome shareholders to own 92.4% of combined company on fully-diluted basis post-merger.","Asset sale to Biorad for $1.6M in cash; concurrent financing totals $7.3M, including $660k bridge notes.","Pro forma weighted-average shares of 7,191,409; combined total assets $6.95M, equity $4.79M.","Merger closed August 14, 2025; filing corrects previously erroneous pro forma calculations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-087217","json":"https://secwatch.observer/filing/0001213900-25-087217.json","markdown":"https://secwatch.observer/filing/0001213900-25-087217.md","text":"https://secwatch.observer/filing/0001213900-25-087217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025087217/0001213900-25-087217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025087217/ea0257032-8ka1_vyome.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:44:00.551258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}